Researchers at NYU Langone Health have developed a gene-based blood test that uses circulating tumor DNA (ctDNA) to predict early melanoma recurrence.

The ctDNA test detects mutated DNA released into the bloodstream by dying melanoma cells.

A study of nearly 600 stage III melanoma patients revealed that 80% with detectable ctDNA experienced cancer recurrence significantly faster than those without. This data underscores the ctDNA test's potential to transform melanoma monitoring.

By isolating genetic mutations found in melanoma cells, the ctDNA test provides a clear picture of disease activity. It is a cutting-edge alternative to outdated imaging techniques, enhancing earlier detection and better treatment decision-making.

Mahrukh Syeda, the study's lead author, suggests ctDNA testing can help doctors identify which patients are likely to respond to therapy, leading to more personalized treatment plans for better outcomes.

The success of ctDNA testing in melanoma mirrors findings in other cancers. Early detection through a blood test can enable timely treatment interventions, crucial for cancers known to be difficult to manage once spread.

Routine ctDNA monitoring could become a standard in melanoma management. As the medical field moves toward precision medicine, refining this test will enhance patient care and survival rates, marking a new era in cancer diagnostics.